Neurotech International Ltd.
AASX:NTI0.02
AUD
0.00
(0.00%)
ISIN
AU000000NTI9
Return %
Stock
S&P 500
1Y
12.50
14.20
3Y
-67.27
81.12
5Y
-64.00
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Anthony Filippis
- Full Time Employees
- 18
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 55 Collins Street Melbourne VI Australia 3000
- IPO Date
- Nov 4, 2016
- Website
- neurotechinternational.com
- Similar Companies
- Business
- Neurotech International Limited (ASX:NTI), a clinical-stage biopharmaceutical development company founded in 2016 and headquartered in Nedlands, Western Australia, focuses on the research, development, and commercialization of innovative therapies for paediatric neurological disorders; its lead product, NTI164, comprises a broad-spectrum oral cannabinoid drug therapy demonstrating potent anti-neuroinflammatory effects in preclinical studies and statistically significant benefits across clinically validated measures of communication, anxiety, socialisation, and irritability in completed Phase I/II and Phase II/III randomised, double-blind, placebo-controlled trials for Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), and Rett Syndrome; the company also advances Mente, a clinically proven home-based neurofeedback therapy device enhancing engagement and relaxation in autistic children with elevated delta band brain activity. Neurotech holds an exclusive worldwide licence for NTI164, with patents pending, and targets prescription-only regulation while conducting operations primarily in Australia and preparing for global expansion through late-stage clinical programs. Recent developments include the extension of the NTI164 Rett Syndrome trial to 52 weeks announced in 2025, receipt of a A$4.73 million R&D tax incentive refund from the Australian Government in November 2025 to bolster its cash position by approximately 267% and fund ongoing clinical pipelines, completion and positive topline results from the Phase II/III ASD trial, human ethics clearance for a Phase I/II trial in spastic cerebral palsy, and a director's increased stake via options acquisition.